Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Europe's STOXX 600 was slightly down at the start of a holiday-shortened week, after clocking its steepest weekly drop since ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...